Gram-negative pathogens resistant to amikacin and other aminoglycosides of clinical 17 relevance usually harbor the 6'-N-acetyltransferase type Ib [AAC(6')-Ib], an enzyme that 18 catalyzes inactivation of the antibiotic by acetylation using acetyl-CoA as donor 19 substrate. Inhibition of the acetylating reaction could be a way to induce phenotypic 20 conversion to susceptibility in these bacteria. We have previously observed that Zn +2 21 acts as an inhibitor of the enzymatic acetylation of aminoglycosides by AAC(6')-Ib, and 22
in complex with ionophores it effectively reduced the levels of resistance in cellulo. We 23 compared the activity of 8-hydroxyquinoline, three halogenated derivatives, and 5- [N-24 Methyl-N-Propargylaminomethyl]-8-Hydroxyquinoline in complex with Zn +2 to inhibit 25 growth of amikacin-resistant Acinetobacter baumannii in the presence of the antibiotic. 26
Two of the compounds, clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) and 5,7-27 diiodo-8-hydroxyquinoline, showed robust inhibition of growth of the two A. baumannii 28 clinical isolates that produce AAC(6')-Ib. However, none of the combinations had any 29 activity on another amikacin-resistant A. baumannii strain that possesses a different, 30 still unknown mechanism of resistance. Time-kill assays showed that the combination 31 of clioquinol or 5,7-diiodo-8-hydroxyquinoline with Zn +2 and amikacin was bactericidal. 32 Introduction 39 Among many mechanisms bacteria have evolved to resist antibiotics, enzymatic 40 modification is one of the most efficient [1, 2] . In the case of aminoglycosides, 41 bactericidal antibiotics used to treat a wide range of bacterial infections, the most 42 relevant mechanisms of resistance in the clinics are enzymatic inactivation by 43 acetylation, nucleotidylation, or phosphorylation [2] [3] [4] . Although more than hundred 44 aminoglycoside modifying enzymes have been identified in bacterial pathogens, the 45 acetyltransferase AAC(6')-Ib, which mediates resistance to amikacin and other 46 aminoglycosides, is the most widespread among Gram-negative clinical isolates [5] [6] [7] . 47
The progressive acquisition of this gene is eroding the usefulness of amikacin as well as 48 other aminoglycosides. One way to overcome this problem is the design of new 49 antimicrobials such as the recent introduction of plazomicin [8] . However, since this is 50 a slow and expensive process and resistance will inevitably develop against the new 51 antibiotics, these efforts must be complemented by other strategies to prolong the useful 52 life of existing drugs [2, 3, 9-11]. In the case of aminoglycosides, in addition to design of 53 new molecules [8, 12, 13] , there is active research to find inhibitors of expression of 54 aminoglycoside modifying enzymes [14-18] and to design enzymatic inhibitors [2, 3, 10, 55 11, 19 -22] . A recent breakthrough in the search for inhibitors of enzymatic inactivation 56 of aminoglycoside was the finding that Zn +2 and other metal ions inhibit the acetylation 57 of aminoglycosides mediated by AAC(6')-Ib in vitro [23] . Although concentrations 58 beyond toxic levels were needed to interfere with resistance in growing bacteria, further 59 research showed that the action of the metal was enhanced when complexed to 60 ionophores, in which case low concentrations were sufficient to overcome resistance in 61 several aminoglycoside-resistant bacteria [23] [24] [25] [26] . We recently showed that two classes 62 of ionophores, clioquinol (5-chloro-7-iodo-8-hydroxyquinoline)(CI8HQ) and pyrithione 63 (N-hydroxypyridine-2-thione), when complexed to Zn +2 or Cu +2 , significantly reduce the 64 levels of resistance to amikacin in Escherichia coli, Klebsiella Enzymatic acetylation assays 87 Acetylation activity was assessed using the phosphocellulose paper binding assay as 88 described previously [35, 36] . Amikacin and [Acetyl-1-14 C]-Acetyl Coenzyme A were 89 used as substrates in reactions carried out in the presence of the soluble content of cells 90 that were disrupted by sonication as described previously [37] . The reactions were 91 carried out in a final volume of 25 μl containing 200 mM Tris-HCl, pH 7.6, 200 μM 92 amikacin, 0.5 μCi [Acetyl-1-14 C]-Acetyl Coenzyme A (specific activity, 60 mCi/mmol), 93 and the enzymatic extract (120 μg protein). The reaction mixtures were incubated at 94 37°C for 1 h and then 20 μl were spotted on phosphocellulose paper strips. The 95 unreacted radioactive donor substrate was eliminated from the phosphocellulose paper 96 by submersion in 1 l hot water (80°C) followed by several washes with water at room 97 temperature. The phosphocellulose paper strips were allowed to dry before 98 determining the radioactivity. 
Results

131
Combination therapies consisting of an antibiotic and an inhibitor of resistance can 132 be an invaluable tool in the search for solutions to the multidrug resistance problem 133 [11] . While this strategy has already been reduced to practice in the case of pathogens 134 resistant to β-lactams [40], efforts to develop inhibitors of resistance to aminoglycosides 135 are still in experimental stages. We have recently found that ionophores complexed to 136 Zn +2 or Cu +2 could be potentiators that decrease the levels of resistance to amikacin in 137 K. pneumoniae and A. baumannii clinical isolates [23] [24] [25] . Since one of the ionophores 138 that in complex with Zn +2 demonstrated activity as an inhibitor of the resistance to 139 amikacin was CI8HQ, a substituted 8-hydroxyquinoline (8HQ), we expanded our studies 140 to other compounds with these characteristics. Fig 1 shows the compounds tested in this 141 work. The tests were carried out using as models three A. baumannii clinical isolates, 142 two of them harboring the aac(6')-Ib gene [32, 33] . The third strain, which does not carry 143 this gene, exhibits resistance to amikacin by a different mechanism. Although this 144 mechanism remains to be elucidated, it most probably consists of phosphorylation 145 mediated by the aphA6 gene found in its genome [33, 34] . 146 Growth curves in the presence of incremental concentrations of amikacin showed 150 that the strains harboring aac(6')-Ib, A144 and A155, can grow in up to 16 μg/ml of the 151 antibiotic (S1 Fig, A and B) . Conversely, strain Ab33405 had a different behavior, while 152 the lag phase became longer as the amikacin concentration was increased, healthy
growth was observed at all tested concentrations (S1 Fig, C) . These results are in 154 agreement with the finding that the latter strain resists amikacin using a mechanism 155 different from that in strains A144 and A155. To confirm that A. baumannii Ab33405 is 156 not able to mediate enzymatic acetylation of amikacin, the total soluble protein extracts 157 of all three strains were used in in vitro acetylation assays using amikacin and AcetylCoA 158
as substrates. The growth of all three A. baumannii strains was unaffected by the presence of 25 or 168 50 μM ZnCl2 or up to 10 μM 8HQ, CI8HQ, 5-[N-Methyl-N-propargylaminomethyl]-8-169 hydroxyquinoline (MP8HQ), or 5,7-diiodo-8-hydroxyquinoline (II8HQ) (S1 Fig, A-C) . 170
Conversely, 10 μM 7-Bromo-8-hydroxyquinoline (B8HQ) was toxic to all three strains, 171 and while strains A155 and Ab33405 could grow in the presence of up to 5 μM, strain 172 A144 growth was inhibited at 1 μM B8HQ (S1 Fig, A-C) . 173 bacteria were identified, their activity as potentiators of amikacin was determined. 175
These assays showed that CI8HQ and II8HQ were the only 8HQ derivatives that 176 mediated phenotypic conversion to susceptibility to amikacin in strains A144 and A155 177 ( Fig 2) . Inspection of these results also showed that after 16 h, strain A155 started to 178 grow when the ionophore tested was II8HQ. We do not yet have a satisfactory 179 explanation for this observation. The ionophores 8HQ and MP8HQ were unable to 180 induce any modification in the growth of strains A144 and A155 in the presence of 181 amikacin and ZnCl2 (Fig 2) . The tests where the ionophore used was B8HQ showed a 182 reduction in growth in the presence of combinations that included B8HQ but either 183 amikacin or ZnCl2 were omitted suggesting that the toxic effect of B8HQ is playing a role 184 in growth inhibition rather than interference with acetylation of amikacin (Fig 2) . Strain 185
Ab33405 showed healthy growth in the presence of either of the ionophores plus 186 amikacin and ZnCl2 confirming that the inhibition by Zn +2 is specific for resistance 187 mediated by the modifying enzyme. Only one condition showed modest inhibition of 188 growth (see The results described above showed that CI8HQ and II8HQ were the most efficient 207 ionophores that in complex with Zn +2 were able to mediate a conversion to susceptibility 208 to amikacin in those A. baumannii strains in which resistance is mediated by AAC(6')-Ib. 209
The bactericidal effect of the combination ionophore-zinc and amikacin was confirmed 210 using time-kill assays. Amikacin at a concentration as low as 8 μg/ml showed a robust 211 bactericidal activity on A. baumannii A144 and A155 strains in the presence of the 212 complexes (Fig 3) . As expected, these strains did not lose viability when incubated with 213 the antibiotic or any other combination of components that did not include all three of 214 them (Fig 3) . Also expected was the absence of bactericidal effect when the 215 combinations ionophore-zinc plus amikacin were added to cultures of A. baumannii 216 Ab33405 or the ionophore utilized was 8HQ (Fig 3) . These results confirmed that 217 amikacin can regain its bactericidal power in the presence of Zn +2 ions when resistance 218 is due to AAC(6')-Ib-mediated acetylation. 219 Effect of ionophore-zinc complexes on resistance to amikacin in A. baumannii strains. A. baumannii A155 (panels to the left), A144 (center panels) or Ab33405 (panels to the right) were cultured in 100 μl Mueller-Hinton broth in microtiter plates at 37°C, with the additions indicated in the figure and the OD600 was periodically determined. The concentrations used were 8 μg/ml amikacin, 25 μM ZnCl2, 5 μM ionophore. A, amikacin; Z, ZnCl2. Time-kill assay curves for amikacin in the presence of ionophore-zinc complexes. A. baumannii A155 (panels to the left), A144 (center panels) or Ab33405 (panels to the right) were cultured in 100 μl Mueller-Hinton broth in microtiter plates at 37°C, with the additions indicated in the figure and the OD600 was periodically determined. A, amikacin; Z, ZnCl2; I, ionophore. Fig. 4 . Cytotoxicity tests. Cytotoxicity on HEK293 cells treated with the indicated concentrations of the different compounds for 24 h was assayed using a LIVE/DEAD kit. The percentage of dead cells was calculated relative to the cells treated with DMSO. Cells incubated with 0.1% Triton X-100 for 10 min were used as a control for maximum toxicity. Experiments were conducted in triplicate and the values are mean ± SD. Black bars show survival in the presence of 5 μM ionophore. Stippled bars show survival in the presence of 5 μM ionophore, 25 μM ZnCl2, and 8 μg/ml amikacin. The same concentrations were used to determine survival in amikacin (white bar) and ZnCl2 (hatched bar). The concentration of DMSO used in the control was μM (gray bar).
